IPSC

Over the past six months, Century Therapeutics reported Q1 and Q2 2026 financial results, confirming CNTY-813 is on track for an IND filing in Q4 2026 with initial clinical data expected in H2 2027, and CNTY-308 is anticipated to enter clinical testing in 2026. Joseph Truitt was appointed to the Board of Directors on September 9, 2026. The company presented new preclinical data for its CNTY-813 islet replacement therapy in June 2026, demonstrating durable glucose control and immune evasion, with further presentations scheduled for October 2026. Analysts have given the company a consensus 'Hold' rating with an average price target of $4.75. Insider trading activity shows more selling than buying in the last three months, and shareholders have experienced substantial dilution, with shares outstanding increasing by 67.40% in one year.